Abstract 17193: Oral Anticoagulation in Addition to Dual Anti-platelet Therapy is Essential in Atrial Fibrillation Patients Experiencing Acute Myocardial Infarction With Percutaneous Coronary Intervention

Introduction: Oral anticoagulants (OACs) and dual anti-platelet therapy (DAPT) is needed to reduce thromboembolism and stent thrombosis in atrial fibrillation (AF) patients experiencing acute myocardial infarction (AMI) with percutaneous coronary intervention (PCI). Because of the increased risk of major bleeding, DAPT without warfarin is preferred to triple therapy (OACs and DAPT) in real world practice. Aims: We aimed to compare efficacy and safety between triple therapy and DAPT in AF patients undergoing PCI due to AMI. Methods: A total of 18,841AMI patients enrolled in Korean AMI Registry (KAMIR). We analyzed consecutive 1,125 AF patients who underwent PCI and survived at hospital discharge. One-year clinical outcomes were compared between triple therapy group (n=384) and DAPT group (n=741). Primary efficacy end-point was defined as major adverse cardiac and cerebral events (MACCE), composed of death, recurrent MI, repeated PCI, and coronary artery bypass grafting (CABG), and new-onset stroke. Primary...